Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 15;803(1):75-81. doi: 10.1016/j.jchromb.2003.07.016.

Abstract

Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is a 15-domain serine proteinase inhibitor which is of pathophysiological relevance for skin diseases and atopy. Domains 2 and 15 of LEKTI contain six cysteine residues and match the Kazal-type inhibitor motif almost exactly. The other 13 domains seem to be Kazal-type derived but lack the cysteines in positions 3 and 6 usually conserved within this family of inhibitors. Here, we report the recombinant production and comprehensive biochemical characterization of the 7.7 kDa LEKTI domain 6 (LD-6). Testing a selected number of different serine proteinases, we show that both native and recombinant LD-6 exhibit a significant but temporary inhibitory activity on trypsin. Furthermore, the relation of LEKTI domain 6 to Kazal-type inhibitors is confirmed by determining its disulfide bond pattern (1-4/2-3) and its P(1) site located after the second Cys residue of LD-6. The established strategy for the recombinant production of LEKTI domain 6 will enable further investigation of its mode of action and its physiological role.

MeSH terms

  • Amino Acid Sequence
  • Base Sequence
  • Carrier Proteins / biosynthesis*
  • Carrier Proteins / chemistry
  • Carrier Proteins / metabolism
  • DNA Primers
  • Electrophoresis, Polyacrylamide Gel
  • Molecular Sequence Data
  • Proteinase Inhibitory Proteins, Secretory
  • Recombinant Proteins / biosynthesis
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism
  • Serine Peptidase Inhibitor Kazal-Type 5

Substances

  • Carrier Proteins
  • DNA Primers
  • Proteinase Inhibitory Proteins, Secretory
  • Recombinant Proteins
  • SPINK5 protein, human
  • Serine Peptidase Inhibitor Kazal-Type 5